Argus raised the firm’s price target on Colgate-Palmolive to $97 from $88 and keeps a Buy rating on the shares. The analyst cites the firm’s favorable view of the company’s products with natural ingredients and of its new pet foods for younger pets and for older pets with kidney problems. Colgate-Palmolive should remain focused on premium products, online sales, analytics, and productivity improvements, the firm tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CL:
- Colgate-Palmolive price target raised to $96 from $85 at Bernstein
- Colgate-Palmolive price target raised to $93 from $85 at Morgan Stanley
- Colgate-Palmolive price target raised to $88 from $80 at Wells Fargo
- Colgate-Palmolive upgraded to Outperform from Market Perform at Raymond James
- Colgate-Palmolive price target raised to $91 from $90 at JPMorgan
